s-1在非小细胞肺癌III期的研究.pdfVIP

V O L U M E 2 8 N U M B E R 3 6 D E C E M B E R 2 0 2 0 1 0 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study Isamu Okamoto, Hiroshige Yoshioka, Satoshi Morita, Masahiko Ando, Koji Takeda, Takashi Seto, Nobuyuki Yamamoto, Hideo Saka, Kazuhiro Asami, Tomonori Hirashima, Shinzoh Kudoh, Miyako Satouchi, Norihiko Ikeda, Yasuo Iwamoto, Toshiyuki Sawa, Masaki Miyazaki, Kenji Tamura, Takayasu Kurata, Masahiro Fukuoka, and Kazuhiko Nakagawa From the Kinki University Faculty of Medicine; Osaka City General Hospital; A B S T R A C T National Hospital Organization, Kinki- chuo Chest Medical Center; Osaka Prefectural Medical Center for Respira- Purpose tory and Allergic Diseases; Osaka City The primary goal of this open-label, multicenter, randomized phase III trial was to determine University Medical School; Cancer whether treatment with carboplatin plus the oral fluoropyrimidine derivative S-1 was noninferior Center, Izumi Municipal Hospital, versus that with carboplatin plus paclitaxel with regard to overall survival (OS) in chemotherapy- Osaka; Kurashiki Central Hospital, naive patients with advanced non–smal